1-2 of 2
Martin Barrett, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)

Andrew Davies, MD, Francesco Merli, Biljana Mihaljevik, Noppadol Siritanaratkul, MD, Philippe Solal-Céligny, MD, Axel Boehnke, Claude Berge, Christine McIntyre, Martin Barrett, PhD, David Macdonald, MD, FRCPC
Journal: Blood
Blood (2012) 120 (21): 1629.
https://doi.org/10.1182/blood.V120.21.1629.1629
Published: 2012
Journal Articles

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Annika Dufour, MD, S. K Bohlander, PhD, Karsten Spiekermann, MD, Stephanie Schneider, Jan Braess, MD, Purvi Kakadiya, Kirsten E Mundt, PhD, Helen Smith, Ming Lin, PhD, Martin Barrett, PhD, Deborah Hurst, MD, Anna Dmoszynska, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Boris V Afanasiev, MD, John Catalano, MBBS, FRACP, FRCPA, Marco Montillo, Christian H. Geisler, MD, Sergey I Moiseev, MD, Philippe Solal-Celigny, MD, Tadeusz Robak, Wolfgang Hiddemann, MD
Journal: Blood
Blood (2010) 116 (21): 1390.
https://doi.org/10.1182/blood.V116.21.1390.1390
Published: 2010